Analysts Expect Opko Health Inc. (OPK) to Announce -$0.08 Earnings Per Share

Equities analysts expect Opko Health Inc. (NASDAQ:OPK) to announce earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Opko Health’s earnings, with estimates ranging from ($0.11) to ($0.07). Opko Health also posted earnings per share of ($0.08) in the same quarter last year. The firm is expected to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.24) per share for the current financial year, with EPS estimates ranging from ($0.30) to ($0.14). For the next fiscal year, analysts forecast that the company will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.34) to ($0.21). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.06. The company had revenue of $263.69 million during the quarter, compared to analysts’ expectations of $260.37 million. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%.

Several equities research analysts have recently weighed in on the stock. ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. Barrington Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of Opko Health in a research report on Wednesday, May 9th. Zacks Investment Research cut shares of Opko Health from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. BidaskClub cut shares of Opko Health from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 27th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of Opko Health in a research report on Tuesday, May 8th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $10.95.

Opko Health traded down $0.08, hitting $5.42, during trading hours on Friday, MarketBeat Ratings reports. The company had a trading volume of 6,292,497 shares, compared to its average volume of 7,250,249. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.94. Opko Health has a 1 year low of $2.66 and a 1 year high of $7.24.

In other news, CEO Phillip Md Et Al Frost bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The stock was bought at an average price of $5.45 per share, with a total value of $54,500.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $16,725,782.95. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 562,719 shares of company stock valued at $2,541,630 in the last three months. 42.74% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC increased its stake in Opko Health by 3.5% during the 2nd quarter. Essex Investment Management Co. LLC now owns 285,700 shares of the biotechnology company’s stock valued at $1,343,000 after purchasing an additional 9,697 shares in the last quarter. Shufro Rose & Co. LLC increased its stake in Opko Health by 5.7% during the 2nd quarter. Shufro Rose & Co. LLC now owns 210,200 shares of the biotechnology company’s stock valued at $988,000 after purchasing an additional 11,300 shares in the last quarter. RPg Family Wealth Advisory LLC increased its stake in shares of Opko Health by 74.3% in the second quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 13,250 shares during the period. Teachers Advisors LLC increased its stake in shares of Opko Health by 3.5% in the fourth quarter. Teachers Advisors LLC now owns 489,837 shares of the biotechnology company’s stock worth $2,400,000 after acquiring an additional 16,675 shares during the period. Finally, Boulegeris Investments Inc. increased its stake in shares of Opko Health by 7.4% in the first quarter. Boulegeris Investments Inc. now owns 245,605 shares of the biotechnology company’s stock worth $779,000 after acquiring an additional 16,825 shares during the period. 23.55% of the stock is owned by institutional investors.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Story: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply